IP Library Granted Patent US 8,067,596
Granted Patent B2
US 8,067,596 · App. 12/316,974 · Granted Nov 29, 2011

Processes for the production of (+)- “Nal” morphinan compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,067,596
App. No.
12/316,974
Granted
Nov 29, 2011
Kind
B2
Abstract

The invention generally provides processes and intermediate compounds useful for the production of (+) nal morphinan compounds. In particular, the process encompasses synthetic routes for the production of (+) nal morphinan compounds or derivatives of (+) nal morphinan compounds from (+)-morphinan substrates such as (+)-hydrocodone, (+)-norhydrocodone or derivatives of either compound.

Claims (37)

1. A process for preparing compound 2-1, the process comprising contacting compound 2-1 (a) with a halogen, X, to form compound 2-1(b), and contacting compound 2-1(b) with a proton acceptor to form compound 2-1 according to the reaction scheme:

wherein:

R 1 and R 2 are independently selected from the group consisting of hydrogen, hydrocarbyl, substituted hydrocarbyl, and a protecting group;

R 5 , and R 6 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

R 7 is selected from the group consisting of hydrogen and hydroxyl; and

Y is selected from the group consisting of oxygen, sulfur, and nitrogen.

2. The process of claim 1 , wherein:

R 1 and R 2 are independently selected from the group consisting of hydrogen, alkyl, vinyl, aryl, {—}CH 2 -aryl, acyl, alkoxycarbonyl, trialkylsily, oxygen protecting group, and a nitrogen protecting group;

R 5 , R 6 , and R 7 are each hydrogen;

Y is oxygen; and

wherein the halogenation reaction is conducted in the presence of an organic solvent, the molar ratio of compound 2-1 (a) to halogen is from about 1:2 to about 1:10, and the halogenation reaction is conducted at a temperature ranging from about −40° C. to about 20° C.; the molar ratio of compound 2-1 (b) to proton acceptor is from about 1:1 to about 1:10 and the reaction is conducted at a temperature ranging from about 80° C. to about 140° C. in the presence of an aprotic solvent; and the configuration of carbons 5, 13, 14, and 9, respectively, of compounds comprising formulas 2-1(a), 2-1(b) and 2-1 is selected from the group consisting RRRS, RRSS, SRRS, SRSS, RSRR, RSSR, SSRR, and SSSR.

3. A process for the preparation of compound 8-1 according to the following reaction scheme:

wherein:

R 1 and R 2 are independently selected from the group consisting of hydrogen and methyl;

R 1a is selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl;

R 3 is selected from the group consisting of alkyl, substituted alkyl, aryl, and substituted aryl;

R 4 is selected from the group consisting of hydrocarbyl, and substituted hydrocarbyl;

R 5 , and R 6 are independently selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , SH, hydrocarbyl, and substituted hydrocarbyl, wherein R 5 , and R 6 may together form a group selected from the group consisting of =0, and ═S;

R 7 is selected from the group consisting of hydrogen, halogen, hydroxyl, NH 2 , CN, hydrocarbyl, and substituted hydrocarbyl;

X is selected from the group consisting of halogen and hydrogen; and

Y is selected from the group consisting of oxygen, sulfur, and nitrogen, and

wherein compound 2-1 is prepared by a process comprising contacting compound 1-1 with an alcohol scavenger in the presence of a proton donor to form compound 2-1 according to the following reaction scheme:

wherein R 1 , R 2 , R 5 , R 6 , R 7 , X, and Y are as defined above, the molar ratio of compound 1-1 to alcohol scavenger to proton donor is from about 1:0.5:2 to about 1:2:20, and the reaction is conducted in the presence of an aprotic solvent at a temperature ranging from about 20° C. to about 100° C., or

wherein compound 2-1 is prepared by a process comprising contacting compound 2-1(a) with a halogen, X, to form compound 2-1(b), and contacting compound 2-1(b) with a proton acceptor to form compound 2-1 according to the reaction scheme:

wherein R 1 , R 2 , R 5 , R 6 , R 7 and Y are as defined above; the halogenation reaction is conducted in the presence of an organic solvent, the molar ratio of compound 2-1(a) to halogen is from about 1:2 to about 1:10, and the halogenation reaction is conducted at a temperature ranging from about −40° C. to about 20° C.; and the molar ratio of compound 2-1(b) to proton acceptor is from about 1:1 to about 1:10 and the reaction is conducted at a temperature ranging from about 80° C. to about 140° C. in the presence of an aprotic solvent.

4. The process of claim 3 , wherein:

R 1a is selected from the group consisting of alkyl, vinyl, aryl, {—}(CH 2 -aryl;

R 4 is selected from the group consisting of alkyl, vinyl, aryl, {—}(CH 2 -aryl;

X is bromide; and

Y is oxygen.

5. The process of claim 3 , wherein R 1a is {—}(CH 2 -cyclopropyl, R 2 is hydrogen, and Y is oxygen.

6. The process of claim 3 , wherein R 1a is {—}(CH 2 —CHCH 2 , R 2 is hydrogen, and Y is oxygen.

7. The process of claim 3 , further comprising a process for preparing compound 1-1, the process comprising contacting a compound comprising SM-1 with bromide to form a compound comprising SM-2, and contacting the compound SM-2 with sodium hydroxide to form the compound comprising 1-1 according to the following reaction scheme:

wherein: R 1 , R 5 , R 6 , and R 7 are as defined in claim 3 .

8. The process of claim 3 , wherein the molar ratio of compound 2-1 to (R 3 CO) 2 O is from about 1:2 to about 1:20, the reaction of Step A is conducted in the presence of an aprotic solvent and at a temperature ranging from about 20° C. to about 100° C.; the molar ratio of compound 3-1 to oxidizing agent is from about 1:1 to about 1:2, the reaction of Step B is conducted in the presence of a protic solvent; at a temperature ranging from about 0° C. to about 100° C.; the molar ratio of compound 4-1 to reducing agent is from about 1:0.0005 to about 1:0.005, the reaction of Step C is conducted in the presence of an aprotic solvent, and at a temperature ranging from about 20° C. to about 120° C.; the molar ratio of compound 5-1 to N-demethylation agent to proton acceptor is from about 1:2:1 to about 1:20:20, the reaction of Step D is conducted in the presence of an aprotic solvent, and at a temperature ranging from about 50° C. to about 120° C.; the molar ratio of compound 6-1 to proton donor is from about 1:2 to about 1:20, the reaction of Step E is conducted in the presence of a protic solvent, and at a temperature ranging from about 80° C. to about 120° C.; the molar ratio of compound 7-1 to R 1a X is from about 1:1 to about 1:2, the reaction of Step F is conducted in the presence of an organic solvent, and at a temperature ranging from about 20° C. to about 120° C.

9. The process of claim 3 , wherein the yield of compound 8-1 is from about 5% to about 45%.

10. The process of claim 3 , wherein the configuration of carbons 5, 13, 14, and 9, respectively, of compounds comprising formulas 1-1 and 8-1 is selected from the group consisting RRRS, RRSS, SRRS, SRSS, RSRR, RSSR, SSRR, and SSSR.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2017
From: MALLINCKRODT LLC
To: SPECGX LLC
Reel/Frame 044891/0376 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
CHANGE OF LEGAL ENTITY Recorded Aug 16, 2011
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 026754/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2009
From: WANG, PETER X.; JIANG, TAO; CANTRELL, GARY L.; BERBERICH, DAVID W.; TRAWICK, BOBBY N.; LIAO, SUBO
To: MALLINCKRODT INC.
Reel/Frame 022182/0580 →